Madrigal
2 known investors
Madrigal is a biopharmaceutical company developing therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious progressive liver disease. Its research led to the first FDA-approved treatment for MASH, aimed at halting or reversing liver fibrosis before cirrhosis develops.
Investors Β· 2
Frequently asked questions
- What does Madrigal do?
- Madrigal is a biopharmaceutical company developing therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious progressive liver disease. Its research led to the first FDA-approved treatment for MASH, aimed at halting or reversing liver fibrosis before cirrhosis develops.
- Who are Madrigal's investors?
- Madrigal's investors include Avoro Capital Advisors, Bay City Capital.